AMGEN INC is 39.9x more valuable than CRISPR Therapeutics AG by market capitalization ($191.70 B vs $4.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CRSP | AMGN |
|---|---|---|
| Market cap | $4.80 B | $191.70 B |
| US-listed rank | #1436 | #79 |
| Revenue (latest FY) | $3.51M | $36.75B |
| Net income (latest FY) | -$581.60M | $7.71B |
| Net margin | -16569.8% | 21.0% |
| P/E (trailing FY) | - | 24.9 |
| SEC filings | 837 | 1,011 |
AMGEN INC is 39.9x more valuable than CRISPR Therapeutics AG by market capitalization ($191.70 B vs $4.80 B).
In their latest fiscal years, CRISPR Therapeutics AG reported $3.51M in revenue while AMGEN INC reported $36.75B.
Full pages: CRISPR Therapeutics AG and AMGEN INC, or browse the full rankings.